Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism University of Manitoba Principal Investigator Diabetes Research Group John Buhler Research Centre Winnipeg, Manitoba, Canada